Farid Menaa Professor/Principal Investigator

• Email:dr.fmenaa@gmail.com
• Department:Department of Internal Medicine and Nanomedicine Fluorotronics
• University:French universities and institutions
• Country:USA

Biography:

Dr. Farid Menaa (Bsc. Eng., Bsc. Bio., Msc. Genetics, Master Gerontology/Geriatric, PhD Radiation Oncology and Gerontology, EMBA Entrepreneurship and MD candidate), is an inter- and multi-disciplinary professional. Professor, Principal Investigator, Director, Consultant Editor, Reviewer, Event Organizer and Entrepreneur, Dr. Menaa earned his degrees with the highest distinctions from prestigious French universities and institutions. Dr. Menaa followed a post-doctoral in Oncology as an NIH-fellow (San Diego, California, USA; 2004-2007). Subsequently, Dr. Menaa pursed his career in Dermatology, and Stem Cells as a DFG-Fellow (Wuerzburg, Germany; 2007–2009).

Then, Dr. Menaa was promoted as Chief Scientific Officer and Vice-President R&D at Fluorotronics, Inc. (CA, USA; 2009-2010), a nanotechnology and fluorine chemical company. Eventually, Dr. Menaa was appointed Principal Investigator in Hematology and Genomics as a FAPESP-Fellow (São Paulo, Brazil; 2010–2012). During his career, Dr. Menaa also followed complementary formations (e.g. Medicine, Pharmacy, Biochemistry, Biophysics, Food Sciences and Technology, Marine Biology, Nano-Biotechnology, Bio-Computation, Bio-Statistics, Business Development and Management, Technological Innovation and Quality). Overall, Dr. Menaa was involved in various R&D projects in multiple areas of medicine/nanomedicine, pharmacy/pharmacology/toxicology, biology, stem cells/tissue engineering, genetics/genomics, fluorine chemistry/biochemistry, biophysics/biophotonics, food science, technology/nanotechnology, and business).

His main current focuses are related to preventive, personalized, translational, integrative and nanomedicine, especially in the areas of oncology, regenerative medicine, and gerontology, in order to prevent and implement early diagnosis and efficient therapy. Dr. Menaa has a strong experience with teaching, research and development, supervision, edition, leadership, coaching, consulting, event organizations, scientific & medical collaborations in several countries. Dr. Menaa is, among others, the leading organizer of the Target Meeting´s 1st World Nanomedicine and Nanobiotechnology Online Conference 2013 (http://www.targetmeeting.com), co-organizer of “Nanomaterials Conference” 2013 (Beijing, China) and 2014 (Shenzhen, China), member of the technical committee of the “3rd ScienceOne Conference on Drug Discovery and Development” 2014 (Dubai, UAE). Dr. Menaa is a member of several prestigious organizations (medical and scientific societies), editor, guest editor and reviewer of a large number of esteemed journals worldwide (>50) (e.g. Current Medicinal Chemistry, International Journal of Nanomedicine, Current Organic Chemistry). Among them, he sits on the prestigious editorial boards of Current Drug Therapy (for which is also the lead guest editor of a special issue on nano-pharmaceuticals), Journal of Nanomaterials & Molecular Nanotechnology (JNMN) (for which he is also a guest editor of a special issue on graphene), Journal of Biomaterials and Nanobiotechnology (JBNB), and Journal of Nanomedicine and Biotherapeutics Discovery (JNBD).

Dr. Menaa authored and co-authored more than 100 publications (including peer-reviewed ISI research and review articles, books, book chapters, conference proceedings, patents). Dr. Menaa is often invited as a speaker, keynote/featured speaker and (co-)chairman to reputed world congresses and institutions, where he is offering speeches in various areas of medicine, sciences and technology. During his spare time, Dr. Menaa enjoys family, arts, sports and travelling

Research Interests:

 The main current focuses are related to preventive, personalized, translational, integrative and nanomedicine, especially in the areas of oncology, regenerative medicine and gerontology, in order to prevent and implement early diagnosis and efficient therapy.